ArticleClinical parkinsonism & related disorders2020
Use of a medication-based algorithm to identify advanced Parkinson's disease in administrative claims data: Associations with claims-based indicators of disease severity.
Article in Clinical parkinsonism & related disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Case Definitions and Data Sources for NNCSS Parkinson Disease Surveillance: A Systematic Review.JAMA network open · 2026Pooled it
- Long-Term Clinical Efficacy, Safety, and Polypharmacy Simplification of Levodopa-Entacapone-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: An 18-Month Longitudinal Study.Journal of clinical medicine · 2026Article
- Clinical Outcomes and Predictors of Response to Levodopa-Entacapone-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: A Retrospective Cohort Study over a 4-Year Period.Pharmaceutics · 2026Article
- Real-World Analysis of Healthcare Utilization, Treatment Patterns, and Economic Burden in Medicare Beneficiaries with Parkinson's Disease: Implications by Levodopa Formulation and Disease Severity.PharmacoEconomics - open · 2025Article
- Effects of specialised physiotherapy on mortality in Parkinson's disease: a prospective observational study.NPJ Parkinson's disease · 2025Article
- Effect of Safinamide on Non-Motor Symptoms and Quality of Life in Parkinson's Disease Patients According to Sex, Age, Disease Duration and Levodopa Equivalent Daily Dose.Brain sciences · 2025Article
- Treatment patterns, health care resource utilization, and costs of chimeric antigen receptor T-cell vs standard therapy for relapsed/refractory mantle cell lymphoma in the United States.Journal of managed care & specialty pharmacy · 2025Article
- Healthcare utilization and costs for patients with Parkinson's disease in Taiwan.BMC neurology · 2025Article
- Tools and criteria to select patients with advanced Parkinson's disease for device-aided therapies: a narrative review.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Comparative Effectiveness of Carbidopa-Levodopa Enteral Suspension and Deep Brain Stimulation on Parkinson's Disease-Related Pill Burden Reduction in Advanced Parkinson's Disease: A Retrospective Real-World Cohort Study.Neurology and therapy · 2022Article
- Advanced-Stage Parkinson's Disease: From Identification to Characterization Using a Nationwide Database.Movement disorders clinical practice · 2022Article
- The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease in England.PharmacoEconomics · 2022Observational
- Does the 5-2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries.BMC neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLack of a gold standard definition for advanced Parkinson's Disease (APD), coupled with absence of disease severity information in diagnostic codes, hinders use of large administrative databases for conducting population health and comparative effectiveness studies.
methodsUsing pharmacy claims data, we created an algorithm to identify APD: any 30-day average levodopa equivalent dose (LED) >1000 mg/day. Using 2013 100% U.S. Medicare claims, we applied this algorithm and used multivariate logistic regression to examine associations between assigned APD status and claims-based indicators of PD severity (any deep brain stimulation, fall, hallucinations, walker, wheelchair, specialty bed, dementia diagnosis, skilled nursing facility, hospice), adjusting for sociodemographic, clinical, and treatment characteristics. Levodopa >1000 mg/day, levodopa >800 mg/day and LED >800 mg/day were used in sensitivity analysis.
resultsIn our sample (
conclusionsMedicare patients classified as having APD via a pharmacy claims-based algorithm had higher odds of having claims-based clinical markers of APD, compared with patients categorized as having mild-moderate PD. This proxy strategy could facilitate future claims-based studies and warrants further refinement and validation using medical records or other clinical sources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.